COO Cooper Companies Inc.

CooperCompanies Announces Global Support for Optometry Giving Sight and March of Dimes, Introduces All-Employee Matching Gifts Program

CooperCompanies Announces Global Support for Optometry Giving Sight and March of Dimes, Introduces All-Employee Matching Gifts Program

Cooper Giving Program Bolsters Company’s Health & Wellness Commitment

SAN RAMON, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced it has selected Optometry Giving Sight and March of Dimes as the beneficiaries of its new global charitable giving program. Through the Cooper Giving program, company employees can donate year-round to both non-profits, with Cooper providing a one-for-one match, up to $5,000 USD annually per employee.

“Giving back has long been part of our culture at Cooper and it’s a privilege to partner with Optometry Giving Sight and March of Dimes to continue this tradition of giving. Both are world-class charitable organizations doing amazing work to bring better health and well-being to people in need,” said President and CEO Albert White. “By focusing Cooper Giving on these causes, our multifaceted support through donations, knowledge and time goes even further to help make the greatest impacts.”

CooperVision is a longstanding partner of Optometry Giving Sight (), which specifically targets the prevention of blindness and impaired vision due to uncorrected refractive error. CooperSurgical selected March of Dimes () as its global charitable partner earlier this year, recognizing the organization’s legacy of leadership, impact and innovation in the fight for the health of all moms and babies.

In parallel to these globally recognized causes, the company will continue to encourage local philanthropic efforts, supporting communities in which employees live and work. These contributions are part of Cooper’s alignment with the United Nations Sustainable Development Goals, including a focus on good health and well-being as well as establishing complementary partnerships.

To learn more about how CooperCompanies gives to its communities, supports industry initiatives for scientific and clinical advancements and promotes sustainable operating practices, visit .

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit .

Contact:

Kim Duncan

Vice President, Investor Relations and Administration

925-460-3663

EN
07/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

 PRESS RELEASE

CooperCompanies Announces Release Date for First Quarter 2026

CooperCompanies Announces Release Date for First Quarter 2026 SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at . About Cooper...

 PRESS RELEASE

CooperCompanies to Present at the J.P. Morgan Healthcare Conference

CooperCompanies to Present at the J.P. Morgan Healthcare Conference SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Al White, President and CEO, will represent the Company in a session scheduled to begin at 5:15pm ET. A live and archived webcast of the event, where applicable, will be available on the CooperCompanies’ website at . About CooperCompaniesCooperCompanies (Nasdaq: COO) is a leading global medical de...

Cooper Companies Inc: 1 director

A director at Cooper Companies Inc bought 1,784 shares at 84.060USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Dire...

CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors Enters into Cooperation Agreement with Browning West SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company’s Board of Directors (the “Board”) has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the “Cooperation Agreement”) with Browning West, LP. (“Browning West”). Mr....

 PRESS RELEASE

CooperCompanies Announces New Chair of the Board and Strategic Review

CooperCompanies Announces New Chair of the Board and Strategic Review SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that its Board of Directors has appointed Colleen Jay to succeed current Chair Robert Weiss, effective January 2, 2026. Mr. Weiss will remain on the Board and stand for reelection for the upcoming year, marking his final term. The Company also announced a formal strategic review aimed at identifying opportunities to enhance long-term shareholder value. “Bob’s vision, industry knowledge, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch